455 results on '"Kaminski, Mark S."'
Search Results
2. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
3. Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208
4. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
5. Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR
6. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
7. Supplementary Methods, Supplementary Figures 1-2, Supplementary Tables 1-4 from Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma
8. Activating STAT6 mutations in follicular lymphoma
9. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma
10. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
11. Survival following salvage therapy for primary refractory peripheral T‐cell lymphomas (PTCL)
12. Fetal Dose from PET and CT in Pregnant Patients
13. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
14. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
15. The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma
16. Fetal Dose from PET and CT in Pregnant Patients.
17. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
18. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy
19. Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin’s lymphoma
20. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433
21. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network
22. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
23. Fetal Dose from Positron Emission Tomography and Computed Tomography in Pregnant Patients.
24. Fetal Dose from Positron Emission Tomography and Computed Tomography in Pregnant Patients.
25. 131 I-Tositumomab therapy as initial treatment for follicular lymphoma
26. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database
27. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: A comprehensive analysis from the NCCN lymphoma outcomes project
28. Clinical application of next generation sequencing in lymphoma
29. Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis
30. The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
31. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
32. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab
33. Case Report: Acute Liver Failure Due to Hepatic Involvement by Hematologic Malignancy
34. Re-Treatment With I-131 Tositumomab in Patients With Non-Hodgkinʼs Lymphoma Who Had Previously Responded to I-131 Tositumomab
35. Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkinʼs Lymphomas
36. Original Articles: (131))I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
37. Observations consistent with autocrine stimulation of hybridoma cell growth and implications for large-scale antibody production
38. Importance of intra-therapy single-photon emission tomographic imaging in calculating tumour dosimetry for a lymphoma patient
39. Radioantibodies: Where Do They Fit in?
40. Acute megakaryocytic leukemia presenting as hypercalcemia with skeletal lytic lesions
41. Radioimmunotherapy of B-cell lymphoma with /131I~anti-B1 (anti-CD20) antibody
42. Feasibility and Safety of Outpatient Bexxar® Therapy (Tositumomab and Iodine I 131 Tositumomab) for Non-Hodgkinʼs Lymphoma Based on Radiation Doses to Family Members
43. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
44. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who reveived iodine-131 tositumomab therapy: conjugate views compared with a hybrid method
45. Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas
46. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas
47. Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016
48. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019
49. Multicentre retrospective study of intravascular large B‐cell lymphoma treated at academic institutions within the United States
50. Do Deauville Scores Improve the Clinical Utility of End-of-Therapy FDG PET Scans for Pediatric Hodgkin Lymphoma?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.